Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations.
Elizabeth TitovaVeronica W KanTara LozyAndrew IpKileen L ShierVittal P PrakashMeghan StarolisSara AnsariKira GoldgirshSeoyeon KimMichael C PellicciaAamirah MccutchenMartinus MegallaThomas S GunningHarvey W KaufmanWilliam A MeyerDavid S PerlinPublished in: Microbiology spectrum (2024)
The study was prompted by a desire to better assess the immune status of patients among our cancer host cohort, one of the largest in the New York metropolitan region. Hackensack Meridian Health is the largest healthcare system in New Jersey and cared for more than 75,000 coronavirus disease 2019 patients in its hospitals. The John Theurer Cancer Center sees more than 35,000 new cancer patients a year and performs more than 500 hematopoietic stem cell transplants. As a result, the work was undertaken to assess the effectiveness of vaccination in inducing humoral and cellular responses within this demographic.
Keyphrases
- immune response
- end stage renal disease
- papillary thyroid
- sars cov
- coronavirus disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- healthcare
- randomized controlled trial
- systematic review
- squamous cell
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- risk assessment
- patient reported outcomes
- toll like receptor
- inflammatory response
- mechanical ventilation